Table 2.
Glomerular disease | Drug | Reference |
---|---|---|
Minimal change disease | Ipilimumab Pembrolizumab |
Kidd et al., 201626 Kitchlu et al., 201723 Kitchlu et al., 2017 |
Membranous nephropathy | Nivolumab | Mamlouk et al., 201924 |
Lupus nephritis | Ipilimumab Nivolumab |
Fadel et al., 200922 Mamlouk et al., 201924 |
Pauci-immune glomerulonephritis | Nivolumab Tremelimumab Nivolumab and ipilimumab Ipilimumab + pembrolizumab Pembrolizumab |
Mamlouk et al., 201924 Mamlouk et al., 201924 Mamlouk et al., 201924 Van den Brom et al., 201627 Gallan et al., 201925 |
IgA nephropathy | Pembrolizumab Nivolumab and ipilimumab Nivolumab |
Mamlouk et al., 201924 Mamlouk et al., 201924 Jung et al., 201628 Kishi et al., 201829 |
C3 glomerulopathy | Pembrolizumab | Mamlouk et al., 201924 |
Focal segmental glomerulosclerosis | Nivolumab | Mamlouk et al., 201924 Daanen et al., 201730 |
Renal vasculitis | Nivolumab | Gallan et al., 201925 |